Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation.
Ataru IgarashiMie Kasai AzumaQuanwu ZhangWeicheng YeAditya SardesaiHenri FolseAmeya ChavanKiyoyuki TomitaAmir Abbas Tahami MonfaredPublished in: Neurology and therapy (2023)
The use of lecanemab plus SoC would improve health and humanistic outcomes with reduced economic burden for patients and caregivers with early AD in Japan.
Keyphrases
- end stage renal disease
- newly diagnosed
- healthcare
- public health
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- mental health
- prognostic factors
- adipose tissue
- risk assessment
- case report
- type diabetes
- palliative care
- skeletal muscle
- cognitive decline
- metabolic syndrome
- climate change
- weight loss
- human health
- social media
- patient reported